A Point-of-Care Biomarker Diagnostic Platform…
Infectious Diseases, Human Ophthalmology & More
A Dry Eye & Biomarker Diagnostic Platform
Summary of the Diagnostic Technology Platform
LacriSciences, LLC is a pre-clinical Delaware corporation based in Baltimore, MD. LacripenThe Company has developed a novel hand held device (the LacriPen, Figure 1) utilizing proprietary Surface Plasmon Resonance (SPR) technology that can perform a wide range of diagnostic functions, including rapid point-of-care quantitative measurement of analytes in various bodily fluids within seconds. The device can be used in vivo with bodily fluids such as urine, saliva, mucus, vaginal fluid, serum, etc., plus in vitro measurements such as the quantitative determination of biomarkers in tear film for Eyecare.
The LacriPen utilizes a low-cost single use disposable plastic sensor cap (Figure 2) which is made specific for virtually any target substance whose chemical constituents are being identified and measured (an analyte) through the attachment of analyte-specific antibodies or genetic markers to the small (1×3 mm) inexpensive gold surface of the cap, i.e., the sensing surface. The biochemistries for attaching biofilms to the gold-coated sensor cap have been designed in such a way that not only can many different antibodies and genetic markers be used with the pen, but these bio-sensing films can be reproducibly deposited in a high-throughput manner using an in-house robotic bioprinter.
Point-of-Care Diagnostic Applications
LacriSciences Vision, Inc.
In 2020 LSHC formed LacriSciences Vision Inc. (LSV) to commercialize its SPR Diagnostic Technology in the Field of Human Ophthalmology. LSV initially focused on the two biomarkers commonly associated with Dry Eye Disease, Osmolarity (measuring the salt content of tears) and Matrix Metalloproteinase-9 or MMP-9 (a primary biomarker for inflammation). Following regulatory delays relating to COVID and a de-emphasis in Dry Eye by LSV’s strategic partner, together with some advances in producing biofilm-based analytes, LSV is currently working on a broader spectrum of EyeCare-related analytes, including allergy biomarkers (histamines, tryptase, IgG and IgE), bacterial and viral conjunctivitis (Pink Eye and Adenovirus), Inflammation (cytokines), MRSA and Herpes. Reimbursement rates exist for many of these Eyecare tests.
To the best of LSV’s knowledge there are no current competing ocular diagnostic testing technologies that offer quantitative rapid point-of-care testing for a broad range of ophthalmic diseases and conditions, LSV is currently seeking funding to complete its clinical study requirements for Osmolarity and MMP-9.